Results from a phase I safety trial of hAADC gene therapy for Parkinson disease.

Neurology
J L EberlingM J Aminoff

Abstract

In a primate model of Parkinson disease (PD), intrastriatal infusion of an adeno-associated viral (AAV) vector containing the human aromatic l-amino acid decarboxylase (hAADC) gene results in robust gene expression. After gene transfer, low doses of systemically administered l-dopa are converted to dopamine in the transduced striatal neurons, resulting in behavioral improvement without the side effects typically associated with higher doses of l-dopa. These studies led to the initiation of a phase I safety trial. Here we report the findings for the first cohort of five patients. Patients with moderate to advanced PD received bilateral infusion of a low dose of the AAV-hAADC vector into the putamen. PET scans using the AADC tracer, 6-[18F]fluoro-l-m-tyrosine (FMT), were performed at baseline and at 1 and 6 months after infusion as an in vivo measure of gene expression. PET results showed an average 30% increase in FMT uptake (K(i)(c)) in the putamen after gene transfer. Preliminary analysis of clinical data indicates a modest improvement, but absence of a control and the nonblinded analyses make interpretation difficult. Thus far, this gene therapy approach has been well tolerated and shows PET evidence of sustained gene express...Continue Reading

Citations

Jan 29, 2010·European Journal of Nuclear Medicine and Molecular Imaging·Chrissa SiokaAthanassios P Kyritsis
Oct 22, 2010·Journal of Neurology·Alexander L Berry, Thomas Foltynie
Jun 16, 2010·Journal of Neural Transmission·Kathleen A Maguire-Zeiss, Howard J Federoff
Mar 5, 2009·Journal of Inherited Metabolic Disease·Michael Rotstein, Un Jung Kang
Apr 12, 2011·Current Neurology and Neuroscience Reports·Jennifer Witt, William J Marks
May 24, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Waldy San SebastianKrystof S Bankiewicz
Feb 2, 2012·Expert Reviews in Molecular Medicine·Lauren M Watson, Matthew J A Wood
Mar 6, 2009·Gene Therapy·A S Beutler, M Reinhardt
Jun 5, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Janet CunninghamKrystof S Bankiewicz
Oct 29, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Pedro R Lowenstein
Sep 24, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Hemraj B DodiyaJeffrey H Kordower
Nov 6, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Lili WangJames M Wilson
Nov 12, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Biao DongWeidong Xiao
Jun 10, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Piotr HadaczekKrystof S Bankiewicz
Jul 8, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Shin-ichi MuramatsuImaharu Nakano
Nov 26, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Agnieszka CiesielskaKrystof S Bankiewicz
Dec 9, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·N Matthew EllinwoodMarie-Anne Colle
Apr 2, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Andreas S Beutler
Feb 24, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·R Mark RichardsonKrystof S Bankiewicz
May 3, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Terence R FlotteChristian Mueller
Feb 2, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Erik CederfjällTomas Björklund
Jul 26, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Jie BuMarco A Passini
Sep 20, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Zhongya WangMarkus Grompe
Aug 30, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Agnieszka CiesielskaJohn Forsayeth
May 25, 2010·Nature Medicine·Jose A ObesoGlenda Halliday
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yoland SmithMahlon R DeLong
Feb 6, 2009·Proceedings of the National Academy of Sciences of the United States of America·Adrian P KellsKrystof S Bankiewicz
May 8, 2009·Human Gene Therapy·Abdelilah IbrahimiRik Gijsbers
Mar 20, 2012·Human Gene Therapy·Gabriele MittermeyerKrystof S Bankiewicz
Nov 13, 2012·Human Gene Therapy·Shilpa PrabhakarGary J Brenner
Mar 25, 2011·Human Molecular Genetics·William J BowersMiguel Sena-Esteves
Mar 19, 2009·ILAR Journal·Christine Gagliardi, Bruce A Bunnell
Dec 14, 2011·The Neurologist·Maria Cruz Rodriguez-OrozOriol de Fabregues
Apr 5, 2012·Cold Spring Harbor Perspectives in Medicine·Philippe G CounePatrick Aebischer
Apr 7, 2010·Science Translational Medicine·Anders BjörklundDeniz Kirik
May 10, 2012·Journal of Biomedicine & Biotechnology·Lie-Hang ShenYu-Chin Tseng
May 24, 2012·Parkinson's Disease·Rachel Denyer, Michael R Douglas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.